PubMed Health⌕ Search

Biomedical subjects

V Magdolen

Publications and source records attributed to V Magdolen.

61 records · Page 4Linked to original sources
PubMed1988

The 5'-upstream region of the yeast 25S rRNA gene contains a promoter element allowing expression in yeast and E. coli.

The 25S rRNA gene of Saccharomyces cerevisiae is preceded by a bona fide TATA sequence which allows the initiation of transcription--presumably by polymerase II--from the same strand as the 25S rRNA gene. When the promoter fragment is cloned in front of a lacZ gene equipped with an initiation codon but lacking a promoter, this element permits formation of beta-galactosidase both in yeast and E. coli. Using RNA from yeast transformed with the fusion plasmid, we mapped by primer elongation a single initiation site 63 bp downstream from the presumed TATA sequence, i.e. about 53 bp 5' of the 25S rRNA gene. A similar signal at about the same position was observed when RNA from untransformed wild-type yeast was used as a template for primer elongation. These results suggest that transcription from this polymerase II promoter-like element occurs in vivo. A regulatory function could not be assigned to this transcript. Its initiation is not significantly influenced by heme or carbon source, although two boxes of high homology with upstream activation sequences (UAS) mediating heme dependent expression of the iso-1-cytochrome c gene (CYC1) precede the promoter at the appropriate distance.

Amino Acid Sequence↗
PubMed1988

The intron-containing gene for yeast profilin (PFY) encodes a vital function.

The gene coding for profilin (PFY), an actin-binding protein, occurs as a single copy in the haploid genome of Saccharomyces cerevisiae and is required for spore germination and cell viability. Displacement of one gene copy in a diploid cell by a nonfunctional allele is recessively lethal: tetrad analysis yields only two viable spores per ascus. The PFY gene maps on chromosome XV and is linked to the ADE2 marker. The primary transcript of about 1,000 bases contains an intron of 209 bases and is spliced into a messenger of about 750 bases. The intron was identified by comparison with a cDNA clone, which also revealed the 3' end of the transcript. The 5' end of the mRNA was mapped by primer elongation. The gene is transcribed constitutively and has a coding capacity for a protein of 126 amino acids. The deduced molecular weight of

Amino Acid Sequence↗
PubMed1987

The complete nucleotide sequence of the gene coding for yeast adenylate kinase.

The structural gene for yeast adenylate kinase (AKY) has been isolated and analyzed with respect to its nucleotide sequence. Southern and northern analyses imply that the gene is single copy and is transcribed into an mRNA of about 1,100 bases. The flanking regions of the gene contain the canonical elements typical for initiation and termination of transcription of yeast protein coding genes. The amino acid primary structure deduced from the open reading frame is identical with the protein sequence reported for yeast adenylate kinase (Tomasselli et al. 1986) with the exception of an extension of two amino acids (Met-Ser) at the N-terminus and aspartic acid instead of asparagine at the carboxyl end. Yeast adenylate kinase reveals a striking homology with both the mammalian cytosolic and, particularly, with the mitochondrial isozyme. It has an insertion of 31 amino acids in the middle segment of the protein, when compared to the cytosolic version of the mammalian enzyme. A strikingly conserved insert sequence of the same length and at exactly the same position is present in the mammalian mitochondrial isozyme. The question of the subcellular location of the yeast enzyme is discussed.

Adenylate Kinase↗
PubMed1986

Kinetics of the intracellular availability of heme after supplementing a heme-deficient yeast mutant with 5-aminolevulinate.

The 5-aminolevulinic acid synthetase-deficient yeast mutant ole3 (Bard, M., Woods, R.A. & Haslam, J.M. (1974) Biochem. Biophys. Res. Commun. 56, 324-330), pregrown in a 5-aminolevulinic acid containing medium, can grow on glucose or galactose medium in the absence of heme for about 13 generations. When supplemented with 5-aminolevulinate before their 9th cell division, the cells can be induced to full respiratory competence. From the measurement of heme-dependent parameters (e.g. respiration, transcription of iso-1-cytochrome c mRNA and the post-translational proteolytic processing of the heme-free intermediate precursor of cytochrome c1 to its heme-containing mature form) it can be judged that heme is available in the cell about one hour after the addition of 5-aminolevulinate. The onset of respiration, however, does not occur to an appreciable extent before the 3rd hour of induction. The heme analogue deuteroporphyrin IX prevents respiratory adaptation but yet effects the transcription of heme-controlled genes.

Aminolevulinic Acid↗
PubMedDate not supplied

Inhibition of the interaction of urokinase-type plasminogen activator (uPA) with its receptor (uPAR) by synthetic peptides.

Focusing of the serine protease urokinase-type plasminogen activator (uPA) to the cell surface via interaction with its specific receptor (uPAR, CD87) is an important step for tumor cell invasion and metastasis. The ability of a synthetic peptide derived from the uPAR-binding region of uPA (comprising amino acids 16-32 of uPA; uPA(16-32)) to inhibit binding of fluorescently labeled uPA to uPAR on human promyeloid U937 cells was assessed by quantitative flow cytofluorometric analysis (FACS) and compared to the inhibitory capacities of other synthetic peptides known to interfere with uPA/uPAR-interaction. An about 3000-fold molar excess of uPA(16-32) resulted in 50% inhibition of pro-uPA binding to cell surface-associated uPAR. Using a solid-phase uPA-ligand binding assay employing recombinant soluble uPAR coated to microtiter plates, the minimal binding region of wild-type uPA was determined. The linear peptide uPA(19-31) and its more stable disulfide-bridged cyclic form (cyclo(19,31)uPA(19-31)) displayed uPAR-binding activity whereas other peptides such as uPA(18-30), uPA(20-32) or uPA(20-30) did not react with uPAR. Cyclic peptide derivatives of cyclo(19,31)uPA(19-31) in which certain amino acids were deleted and/or replaced by other amino acids as well as uPAR-derived wild-type peptides did also not inhibit uPA/uPAR-interaction. Therefore, the present investigations identified cyclo(19,31)uPA(19-31) as a potential lead structure for the development of uPA-peptide analogues to block uPA/uPAR-interaction.

Amino Acid Sequence↗
PubMedDate not supplied

Cathepsin B, plasminogenactivator-inhibitor (PAI-1) and plasminogenactivator-receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer.

To evaluate the possible role of cysteine proteases and serine proteases, as well as their respective inhibitors and receptors, as new prognostic factors in NSCLC, we examined, for the first time, 10 biological parameters related to three proteolytic systems within a homogeneous collective of 147 cases of NSCLC. Activities (cath B(AT), cath B(A7.5)) and protein levels of cath B(C), cath L(C), uPA, PAI-1, uPAR [measured by three different assays uPAR (ADI), uPAR (HD13), uPAR (IIIF10)] and TF were measured in homogenates of lung tumour tissue and corresponding non-malignant lung parenchyma. Total cath B activity (cath B(AT)) and enzymatic activity of the fraction of cath B, which is stable and active at pH 7.5 (cath B(A7.5)), were determined by a fluorogenic assay using synthetic substrate Z-Arg-Arg-AMC. The concentrations of cath B(C), cath L(C), uPA, PAI-1, uPAR and TF were determined by ELISAs. uPAR was determined using three different ELISA formats. The median levels of cath B(AT) (5.1-fold), cath B(A7.5) (2.5-fold), cath B(C), (8.5-fold), cath L(C) (6.6-fold), uPA (6.5-fold), PAI-1 (4.2-fold), uPAR (ADI) (2.2-fold), uPAR (HD13) (4.0-fold) and uPAR (IIIF10) (2.6-fold) were higher in tumour tissue compared to the lung parenchyma. Cath B(AT), cath B(A7.5) and cath B(C) in primary tumours correlated with lymph node metastases. Regarding histologies, the concentration of PAI-1 seems to be associated with the histological cell types of NSCLC. We found the highest values of PAI-1 in large cell carcinoma > SCC, AC > carcinoid and lowest values in metastases of primary tumours of other organs. Only PAI-1 was significantly increased in poorly-differentiated cells (G3) compared to well- and moderately- differentiated cells (G1/G2). PAI-1 significantly correlated with cath B(AT) and cath B(A7.5) with uPAR (ADI), uPAR (HD13), uPAR (IIIF10) with uPA, and only weakly with TF, but not with cath B(C) and cath L(C). Significant correlations with overall survival in the total population of NSCLC patients were observed in univariate analysis for cath B(AT), cath B(C), PAI-1, uPAR (ADI), uPAR (HD13), and uPAR (IIIF10). Cath L(C) was not significantly associated with poor prognosis. Regarding the histological tumour type, only in patients with squamous cell carcinomas did cath B(A7.5) and PAI-1 remain significant prognostic factors. In multivariate survival analysis only two proteolytic factors, PAI-1 and uPAR (III101F), stayed significant. In conclusion, among 10 biological parameters evaluated within the same cohort of patients, only PAI-1, uPAR (ADI), uPAR (HD13), uPAR (IIIF10), cath B(AT) and cath B(C) are prognostic factors for overall survival of NSCLC patients. Moreover, PAI-1 and uPAR (IIIF10) add independent prognostic information with regard to established clinical and histomorphological factors in NSCLC.

Adolescent↗